NEW YORK (GenomeWeb Daily News) – Enzo Biochem said today that its Enzo Life Sciences subsidiary has inked a co-marketing partnership with BioTek Instruments in the area of high-throughput live-cell analysis for drug discovery and research.
Under the partnership, the companies will co-promote BioTek's Precision XS automated sample processor and Synergy Mx multi-mode microplate reader with Enzo's FluoForte calcium assay kit for monitoring intracellular calcium mobilization. The companies said that the combined offering, which will be marketed to research institutions, biotech firms, and pharmaceutical companies, provides a small-scale, cost-effective, and automated cell-based screening approach for identifying GPCR agonists and antagonists.
"A major source of frustration for many researchers has been that selected assays were not compatible with a particular instrument and vice-versa," Peter Banks, scientific director at Bio-Tek, said in a statement.
"The collaboration will provide validated turn-key solutions to the research community," Wayne Patton, Enzo's CSO, said in a statement.
The collaboration will be formally launched at November's MipTec 2009 meeting in Basel, Switzerland, where researchers from both companies will present a poster detailing the combined workflow for screening GPCRs. Drugs targeting GPCRs account for roughly 40 percent of all currently marketed pharmaceuticals, the companies said.